TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01038258

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET scan after course 1 and surgery after 8 courses
Description: PET scan and surgery
Study: NCT04479033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaborative model of community care management
Description: An individualised care plan is developed for PLWDs-caregiver dyads who meet/communicate weekly with various members of the HMDCS team depending on the nature of their needs. Each dyad's care plan involves the diagnosis of problems (eg: memory problems, family conflicts, poor nutrition, fall risk, medication compliance, lack of long-term care arrangements), establishment of treatment goals (eg: caregiver education, awareness of long-term care planning, stabilising medical care at home, improving emotional support), and indicating specific interventions (eg: referrals to counsellors, specialist doctors, day rehabilitation centres; consultations at GP clinic; coordination of advanced care planning; installation of home safety devices; training caregivers to detect acute deterioration in PLWDs). Monitoring of the dyads' statuses and updating of care plans are performed throughout the duration of the programme.
Study: NCT01053260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEARN Program
Description: Participants will receive weekly counseling based on the LEARN Program for Weight Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LEARN Program
Description: Participants will receive weekly counseling based on the LEARN Program for Weight Management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
Study: NCT03704584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Group: Corticosteroid injection
Description: Subjects will receive a corticosteroid injection that is 40 mg/mL injection of Methylprednisolone or 40mg/mL injection of methylacetate injectable suspension or 40 mg/mL triamcinolone.

Intervention type: DRUG
Group type: OTHER
Intervention: Control Group (corticosteroid alone)
Description: Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Group: Lidocaine
Description: Subjects will receive an injection of lidocaine (1% lidocaine HCl).
Study: NCT01083641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 10mg oral three times daily
Study: NCT04500860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose tadalafil 5 mg
Description: Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine 4 Mg Oral Capsule, Extended Release
Description: To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drugs
Study: NCT01777321

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes zoster vaccine GSK1437173A
Description: HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine GSK1437173A
Description: HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
Study: NCT02320032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil
Description: Gluteal IM injection, given once every 4 to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil
Description: Gluteal IM injection, given once every 4 to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil
Description: Gluteal IM injection, given once every 4 to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil
Description: Gluteal IM injection, given once every 4 to 8 weeks
Study: NCT03134014

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: If randomized to a breakfast consuming group, participants will be given breakfasts to consume between 6:00-8:00 am.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: If randomized to a breakfast consuming group, participants will be given breakfasts to consume between 6:00-8:00 am.
Study: NCT00959062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: 5 mcg/kg (maximum 200 mcg) enterally every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Preparation visually identical to clonidine.
Study: NCT03271476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR psychotherapy
Description: Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
Study: NCT03324984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% chloroprocaine
Description: In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% bupivacaine
Description: Bupivacaine is used on label
Study: NCT02710786

Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
Study: NCT00003511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02731664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: Intravenous infusion of GLP-1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline
Description: Control
Study: NCT02347514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes group visit
Study: NCT05177406

Intervention type: OTHER
Intervention: Aimovig
Description: patients newly initiating Aimovig therapy
Study: NCT00076791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 900 mg of TDF combined with 600 mg emtricitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 900 mg of TDF combined with 600 mg emtricitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: 600 mg oral dose of TDF
Study: NCT03975556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored food and diet advice
Description: Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard healthy eating advice
Description: Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate dietary recommendations
Study: NCT00076791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: 600 mg oral dose of TDF
Study: NCT02574000

Intervention type: OTHER
Intervention: ShoulderQ which is a shoulder pain questionnaire
Description: Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.

Intervention type: OTHER
Intervention: Clinical shoulder examination
Description: Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
Study: NCT05494827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular consumption of natural mineral water Borjomi® with high bicarbonate content
Description: Natural mineral water Borjomi® is a transparent mineral water with specific alkaline taste and smell. The chemical composition includes sodium hydrocarbonate (HCO2-) 3995 mg/l (3500-5000 mg/l), chlorides (Cl-) 360 mg/l (250-500 mg/l), and nitrites (NO2-) \<0.005 mg/l (up to 1 mg/l). The Borjomi water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular consumption of processed drinking water Smart Spring®
Description: Processed drinking water Smart Spring® has no colour and smell with delicate specific taste. The chemical composition includes sodium (Na+) 33.6 mg/l, magnesium (Mg2+) 10.03 mg/l, calcium (Ca2+) 34.57 mg/l, chlorides (Cl-) 69.79 mg/l, sulfates (SO42-) 22.00 mg/l, and hydrocarbonates (HCO2-) 96.48 mg/l. The Smart Spring® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular consumption of still drinking water
Description: Still drinking water Святой Источник®is a standard steal drinking water, that has no colour, taste, and smell. The Святой Источник® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. Participants were asked to abstain from mineral water consumption for the entire observation period.
Study: NCT01342822

Intervention type: DEVICE
Intervention: Angioplasty (PROMUS Element™, and Xience™ Prime stent)
Description: Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
Study: NCT03809806

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pelvic Organ Prolapse Quantification (POPQ) staging
Description: Pelvic Organ Prolapse staging before and 1 year after the procedure
Study: NCT02671201

Intervention type: OTHER
Intervention: Education
Description: Different methods in education of emergency ultrasound

Intervention type: OTHER
Intervention: Education
Description: Different methods in education of emergency ultrasound

Intervention type: OTHER
Intervention: Education
Description: Different methods in education of emergency ultrasound
Study: NCT03809806

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Postoperative questionnaire
Description: Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: The Short Form Health Survey (SF 36) questionnaire
Description: patients fulfilled questionnaire before and 1 year after procedure
Study: NCT00760695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dronabinol
Description: tablets, twice daily, for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets, twice daily, for 4 weeks
Study: NCT00031681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study: NCT03957603

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition Suspension (TFP-DM)
Description: Individualized dietary and lifestyle intervention combined with the recommendation of Enteral Nutrition Suspension (TPF-DM, Diason 0.75 kcal/ml)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Nutrition Therpay
Description: Individualized dietary and lifestyle intervention
Study: NCT06049966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: TECENTRIQ C/S.SOL.IN 1200MG/VIAL (20ML) 1 VIAL x 20ML

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML
Study: NCT03003039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB241
Description: Single intravenous infusion (IV) 375 mg/m2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Single intravenous infusion (IV) 375 mg/m2
Study: NCT02332447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone
Description: A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS.
Study: NCT03386396

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate
Description: A high protein/low carbohydrate shake will be given to the child.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High carbohydrate/low protein
Description: A high carbohydrate/low protein shake will be given to the child
Study: NCT01246869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-2-deoxy-D-glucose (FDG)
Description: Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole
Description: Brain scan with radiopharmaceutical imaging tracer that directly assesses tumor hypoxia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [15O]water
Description: Brain scan with imaging tracer used for measuring tumor blood flow/perfusion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Brain scan to assess tumor size and tumor blood flow/perfusion
Study: NCT03494400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training Presential
Description: The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days, more follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training Presential
Description: The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days, more follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training Home-based
Description: The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities, more follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training Home-based
Description: The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities, more follow-up.
Study: NCT03843632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).
Study: NCT02464475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham osteopathic treatment
Study: NCT03320798

Intervention type: OTHER
Intervention: Data record
Study: NCT00784433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alcohol
Description: 150 cc

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alcohol
Description: 150 cc

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: alcohol
Description: 150 cc
Study: NCT00542048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG®-1
Description: EndoTAG®-1 22 mg/m² twice weekly
Study: NCT01119768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
Study: NCT02696122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Group
Description: General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
Study: NCT03020563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Liposomal Bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine
Study: NCT03395808

Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol
Description: IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
Study: NCT03781830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
Study: NCT04707404

Intervention type: PROCEDURE
Intervention: Cranioplasty
Description: The surgery implanted artificial material to repair the skull defect.

Intervention type: PROCEDURE
Intervention: Cranioplasty
Description: The surgery implanted artificial material to repair the skull defect.
Study: NCT04837872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physical Therapy (MPT)
Description: Individualized physical therapy and static progressive splint (flexion with or without extension splint).
Study: NCT02634840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral sagittal split osteotomy
Description: surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve